Physician profile

Stephanie E Boring

Physician Assistant · Edmore, MI

NPI 1942398987

$6,564.51

in general payments reported to CMS, 2019-2025

42 companies · $1,962 in 2025

The $1,962 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$4,742.20

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $1,804.63 2021-2025
Novo Nordisk INC $612.74 2021-2025 Rybelsus, Ozempic, Wegovy
Astrazeneca Pharmaceuticals LP $475.18 2021-2025 Airsupra, Farxiga, Breztri
Lilly USA, LLC $472.66 2021-2025 Mounjaro, Zepbound, Jardiance
Amgen INC. $338.87 2022-2025 Krystexxa, Otezla, Repatha
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $282.25 2021-2025 Caplyta
Astellas Pharma US INC $232.80 2021-2024 Veozah, Myrbetriq
Otsuka America Pharmaceutical, INC. $232.24 2021-2025 Rexulti
Exact Sciences Corporation $213.39 2023-2025 Cologuard Collection Kit, The Cologuard Plus Collection Kit
Lundbeck LLC $149.42 2023-2025 Rexulti
Janssen Pharmaceuticals, INC $148.52 2021-2024 Xarelto, Spravato
Novartis Pharmaceuticals Corporation $129.37 2021-2022
Boehringer Ingelheim Pharmaceuticals, INC. $126.78 2021-2025 Jardiance
Pfizer INC. $116.13 2021-2025
Vanda Pharmaceuticals INC. $114.93 2025 Fanapt
Show all 42 companies
CompanyGeneral paymentsYearsTop products
Axsome Therapeutics, INC. $102.10 2023-2025 Auvelity
Mylan Specialty L.P. $91.41 2022-2024 Yupelri
Horizon Therapeutics Plc $78.72 2021-2023 Krystexxa
Bayer Healthcare Pharmaceuticals INC. $53.73 2022-2023
Glaxosmithkline, LLC. $51.95 2024 Trelegy Ellipta, Arexvy
Teva Pharmaceuticals USA, INC. $50.98 2022-2023 Austedo, Austedo Xr
Dexcom, INC. $50.96 2022-2023 Dexcom G6 Transmitter
E.R. Squibb & Sons, L.L.C. $50.29 2021-2024 Eliquis, Camzyos
Paratek Pharmaceuticals, INC. $49.79 2021-2022
Sanofi-Aventis U.S. LLC $49.58 2021-2022
Eisai INC. $45.57 2025
Xeris Pharmaceuticals, INC. $43.17 2021-2022
Jazz Pharmaceuticals INC. $42.87 2022
Takeda Pharmaceuticals U.S.A., INC. $40.79 2024-2025 Trintellix
Hologic Sales and Service, LLC $38.15 2024 Aptima
Actelion Pharmaceuticals US, INC. $37.98 2025 Uptravi, Opsumit
Neurelis, INC. $37.02 2024-2025 Valtoco
Kyowa Kirin, INC. $33.08 2021-2022
Harmony Biosciences LLC $23.86 2023 Wakix
Sk Life Science, INC. $23.30 2021
Viatris Specialty LLC $21.86 2025 Yupelri
Sanofi Pasteur INC. $20.93 2023
Supernus Pharmaceuticals, INC. $18.33 2021
Philips North America LLC $17.59 2023
Kowa Pharmaceuticals America, INC. $14.94 2022
Biohaven Pharmaceuticals, INC. $13.29 2021
Corium, LLC $12.36 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Stephanie E Boring

$6,564.51

in general payments reported 2019-2025

Years
2021-2025
Top company
Abbvie INC.
Context
The $1,962 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).

https://glasscript.com/doctor/10964247/stephanie-e-boring

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.